CN103402525B - 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法 - Google Patents

使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法 Download PDF

Info

Publication number
CN103402525B
CN103402525B CN201180038334.2A CN201180038334A CN103402525B CN 103402525 B CN103402525 B CN 103402525B CN 201180038334 A CN201180038334 A CN 201180038334A CN 103402525 B CN103402525 B CN 103402525B
Authority
CN
China
Prior art keywords
fucose
fucosylation
cells
analogs
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180038334.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103402525A (zh
Inventor
P·森特
S·阿利
D·本杰明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Priority to CN201710076003.7A priority Critical patent/CN107007615A/zh
Publication of CN103402525A publication Critical patent/CN103402525A/zh
Application granted granted Critical
Publication of CN103402525B publication Critical patent/CN103402525B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201180038334.2A 2010-08-05 2011-08-05 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法 Active CN103402525B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710076003.7A CN107007615A (zh) 2010-08-05 2011-08-05 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
US61/371,116 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710076003.7A Division CN107007615A (zh) 2010-08-05 2011-08-05 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Publications (2)

Publication Number Publication Date
CN103402525A CN103402525A (zh) 2013-11-20
CN103402525B true CN103402525B (zh) 2017-03-01

Family

ID=45560106

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180038334.2A Active CN103402525B (zh) 2010-08-05 2011-08-05 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法
CN201710076003.7A Pending CN107007615A (zh) 2010-08-05 2011-08-05 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710076003.7A Pending CN107007615A (zh) 2010-08-05 2011-08-05 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法

Country Status (21)

Country Link
US (4) US9504702B2 (enExample)
EP (2) EP3513794A3 (enExample)
JP (4) JP5918235B2 (enExample)
KR (2) KR101950520B1 (enExample)
CN (2) CN103402525B (enExample)
AU (3) AU2011285490B2 (enExample)
CA (1) CA2803388C (enExample)
CY (1) CY1121419T1 (enExample)
DK (1) DK2608796T3 (enExample)
ES (1) ES2711622T3 (enExample)
HU (1) HUE043370T2 (enExample)
IL (2) IL224487A (enExample)
MX (1) MX356671B (enExample)
NZ (1) NZ606250A (enExample)
PL (1) PL2608796T3 (enExample)
PT (1) PT2608796T (enExample)
RU (2) RU2017122482A (enExample)
SI (1) SI2608796T1 (enExample)
TR (1) TR201902439T4 (enExample)
WO (1) WO2012019165A2 (enExample)
ZA (1) ZA201300653B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2282773B2 (en) 2008-05-02 2025-03-05 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
PL2608796T3 (pl) * 2010-08-05 2019-04-30 Seattle Genetics Inc Hamowanie fukozylacji białka w warunkach in vivo za pomocą analogów fukozy
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
JP6906520B2 (ja) 2015-12-04 2021-07-21 シージェン インコーポレイテッド チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療
ES2908067T3 (es) * 2016-05-10 2022-04-27 Ares Trading Sa Métodos para modular los perfiles de galactosilación proteicos de proteínas recombinantes empleando peracetil galactosa
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
KR102687149B1 (ko) 2017-06-07 2024-07-24 씨젠 인크. 감소된 표면 푸코실화를 갖는 t 세포 및 이를 생산하고 사용하는 방법
WO2019108639A1 (en) 2017-12-01 2019-06-06 Pfizer Inc. Anti-cxcr5 antibodies and compositions and uses thereof
MY206031A (en) 2018-03-29 2024-11-26 Pfizer Lfa3 variants and compositions and uses thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
JP7446587B2 (ja) * 2018-12-27 2024-03-12 慶應義塾 抗ヒトノロウイルス剤
CN114761427B (zh) * 2019-12-19 2025-10-03 默克专利股份公司 用于调节蛋白质的糖基化谱的方法和组合物
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
KR20230047357A (ko) * 2020-06-03 2023-04-07 시몬 프레이저 유니버스티 단백질 푸코실화 억제제 및 이의 용도
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
MX2023014515A (es) 2021-06-07 2024-01-29 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilacion de proteinas glucosiladas.
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019632A1 (en) * 1991-04-30 1992-11-12 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
WO1998018805A2 (en) * 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 ２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
ATE174925T1 (de) 1991-10-15 1999-01-15 Scripps Research Inst Herstellung von fucosylierten kohlenhydraten durch enzymatische fucosylierungs-synthese der zuckernukleotide; und in situ regeneration von gdp-fucose
DE69425439D1 (de) 1993-09-29 2000-09-07 Nissin Food Products Ltd In stellung 21 substituierte steroide
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd ２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
CA2513399A1 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
JPWO2005017155A1 (ja) 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
CA2542130A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cell genomically modified to produce polypeptides with an altered glycosylation pattern
BRPI0417750A (pt) 2003-12-23 2007-04-10 Progen Ind Ltd composto da fórmula; composição farmacêutica ou veterinária; uso do composto, e método para prevenção e tratamento na área de glicosaminoglicano (gag) miméticos
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
ES2477765T3 (es) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Agentes de unión al anti-cd70 humanizado y usos de los mismos
AR058129A1 (es) 2005-10-21 2008-01-23 Genzyme Corp Productos terapeuticos basados en anticuerpos con actividad de adcc mejorada
ATE485037T1 (de) 2005-11-28 2010-11-15 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
NZ569450A (en) 2005-12-21 2012-01-12 Viventia Biotech Inc An isolated protein comprising a cancer-associated variant of Mammalian Scratch
WO2007081031A1 (ja) 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
EP4092418A1 (en) 2006-02-10 2022-11-23 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
WO2007101148A2 (en) 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
CA2642189A1 (en) 2006-02-24 2007-09-07 University Of Miami Mannose derivatives for killing tumor cells
US8816050B2 (en) 2006-03-22 2014-08-26 The Scripps Research Institute Method of preparing glycopeptides
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
CA2663536A1 (en) 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
CA2677747A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
US7968687B2 (en) 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
AU2009223054A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced ADCC function
EP2282773B2 (en) * 2008-05-02 2025-03-05 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
WO2009143515A2 (en) 2008-05-23 2009-11-26 University Of Miami Treatment using continuous low dose application of sugar analogs
EP2303286A4 (en) * 2008-06-16 2011-12-28 Academia Sinica COMPOSITIONS FOR GENERATING IMMUNE REACTIONS SPECIFIC TO GLOBO H AND SSEA3 AND THEIR USES IN CANCER TREATMENT
WO2010111713A2 (en) 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
WO2011137528A1 (en) * 2010-05-06 2011-11-10 Simon Fraser University Methods and compounds for inhibiting glycosyltransferases
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
PL2608796T3 (pl) 2010-08-05 2019-04-30 Seattle Genetics Inc Hamowanie fukozylacji białka w warunkach in vivo za pomocą analogów fukozy
JP2014505058A (ja) 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
JP6906520B2 (ja) 2015-12-04 2021-07-21 シージェン インコーポレイテッド チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019632A1 (en) * 1991-04-30 1992-11-12 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
WO1998018805A2 (en) * 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
enzymic formation of potential anticancer and antiviral inosine analogs;B.sheid等;《experientia》;19960901;第52卷(第9期);878-881 *
synthesis and biological activity of potential antimetabolites of L-fucose;Jesse等;《Journal of medicinal chemistry》;19791231;第22卷(第8期);971-976 *

Also Published As

Publication number Publication date
MX356671B (es) 2018-06-08
JP2016175909A (ja) 2016-10-06
EP2608796B1 (en) 2018-11-21
US11033561B2 (en) 2021-06-15
RU2013109415A (ru) 2014-09-10
TR201902439T4 (tr) 2019-03-21
JP6622238B2 (ja) 2019-12-18
IL244019A0 (en) 2016-04-21
JP5918235B2 (ja) 2016-05-18
WO2012019165A2 (en) 2012-02-09
AU2016204495A1 (en) 2016-07-21
CA2803388C (en) 2019-11-05
US10342811B2 (en) 2019-07-09
CN107007615A (zh) 2017-08-04
AU2017279653A1 (en) 2018-01-18
MX2013001303A (es) 2014-07-24
CA2803388A1 (en) 2012-02-09
AU2011285490B2 (en) 2016-04-21
KR101950520B1 (ko) 2019-02-20
HUE043370T2 (hu) 2019-08-28
WO2012019165A3 (en) 2013-08-15
AU2011285490A1 (en) 2013-01-10
US20200061091A1 (en) 2020-02-27
JP2020040974A (ja) 2020-03-19
EP3513794A2 (en) 2019-07-24
US20170035790A1 (en) 2017-02-09
JP2017149723A (ja) 2017-08-31
JP6113887B2 (ja) 2017-04-12
PT2608796T (pt) 2019-02-25
ES2711622T3 (es) 2019-05-06
US20210260086A1 (en) 2021-08-26
CN103402525A (zh) 2013-11-20
SI2608796T1 (sl) 2019-03-29
DK2608796T3 (en) 2019-03-18
EP2608796A4 (en) 2014-06-11
US20130129784A1 (en) 2013-05-23
US9504702B2 (en) 2016-11-29
NZ606250A (en) 2015-04-24
EP3513794A3 (en) 2019-10-16
JP2013541503A (ja) 2013-11-14
ZA201300653B (en) 2014-03-26
RU2017122482A3 (enExample) 2019-01-30
KR20190022884A (ko) 2019-03-06
PL2608796T3 (pl) 2019-04-30
RU2017122482A (ru) 2019-01-30
EP2608796A2 (en) 2013-07-03
IL244019B (en) 2019-09-26
IL224487A (en) 2016-07-31
CY1121419T1 (el) 2020-05-29
RU2625768C2 (ru) 2017-07-18
KR20130135240A (ko) 2013-12-10

Similar Documents

Publication Publication Date Title
CN103402525B (zh) 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法
JP2023139267A (ja) Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用
DE212016000029U1 (de) Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
TW201521766A (zh) 碳水化合物疫苗之化合物及組成物以及其用途
TW201628646A (zh) 免疫／治療性醣共軛物組合物及其用途
US20250295798A1 (en) Ligand-drug conjugate of exatecan analogue, and medical use thereof
WO2023016488A1 (zh) 一种基于微管抑制剂的抗体偶联药物
WO2023024949A1 (zh) 一种由可断裂连接子偶联的抗体偶联药物
EP4445919A1 (en) Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof
HK40011525A (en) Fucose analogs for inhibition of protein fucosylation in vivo
HK1186659B (en) Inhibition of protein fucosylation in vivo using fucose analogs
HK1186659A (en) Inhibition of protein fucosylation in vivo using fucose analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant